X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Based on discussions with MHLW and PMDA, Eisai applied to PMDA for permission to utilize "prior assessment consultation" process for BAN2401 (lecanemab), an investigational anti-amyloid beta protofibril antibody with aim of shortening review period for treatment of early AD.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2022
Details:
E7386 is a CBP/β-catenin inhibitor that inhibits CBP and β-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression is expected to suppress tumor.
Lead Product(s): E7386,Lenvatinib
Therapeutic Area: Oncology Product Name: E7386
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: PRISM BioLab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Among the 697 not dMMR patients, 346 patients were randomized to KEYTRUDA plus LENVIMA, and 351 patients were randomized to investigator's choice of doxorubicin (n=254) or paclitaxel (n=97).
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
KEYTRUDA Plus LENVIMA significantly reduced the risk of death by 38%, with a median overall survival of 18.3 months versus 11.4 months with chemotherapy regardless of mismatch repair status.
Lead Product(s): Pembrolizumab,Lenvatinib
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2021
Details:
Aducanumab, an amyloid beta-targeting antibody, has been shown in clinical trials to remove amyloid beta in the brain and significantly slow clinical decline in patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease dementia.
Lead Product(s): Aducanumab
Therapeutic Area: Neurology Product Name: BIIB037
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
The collaboration will use Wren’s network kinetics drug discovery platform, alongside Eisai’s extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Wren Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
